TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Status:
Completed
Trial end date:
2013-01-10
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, double-dummy, multicenter, global Phase 3 study of IV to
oral TR-701 FA 200 mg once daily for 6 days versus IV to oral Zyvox® (linezolid) 600 mg every
12 hours for 10 days for the treatment of ABSSSI in adults. Patients are to start treatment
with at least 2 IV doses and may receive IV therapy for the entire treatment duration.
Approximately 100 to 140 sites globally will participate in this study. Patients with an
ABSSSI caused by suspected or documented gram positive pathogen(s) at baseline will be
randomized 1:1 to study treatment.